<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896911414273</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896911414273</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Renal-Cell Carcinomas in End-Stage Kidneys</article-title>
<subtitle>A Clinicopathological Study With Emphasis on Clear-Cell Papillary Renal-Cell Carcinoma and Acquired Cystic Kidney Disease–Associated Carcinoma</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Bhatnagar</surname><given-names>Ramneesh</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911414273">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Alexiev</surname><given-names>Borislav A.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911414273">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896911414273"><label>1</label>University of Maryland Medical Center, Baltimore, MD, USA</aff>
<author-notes>
<corresp id="corresp1-1066896911414273">Borislav A. Alexiev, MD, Department of Pathology, NBW85, UMMC, 22 S Greene Street, Baltimore, MD 21201, USA Email: <email>balexiev@umm.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>28</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Clear-cell papillary renal-cell carcinoma (CCPC) and acquired cystic kidney disease-associated carcinoma (ACDAC) are neoplasms with distinct morphological characteristics that behave less aggressively than conventional renal-cell carcinomas. End-stage kidney specimens from 61 patients (47 males and 14 females) with 109 renal-cell carcinomas were selected. Papillary renal-cell carcinoma was the most common malignancy (61/109, 56%), followed by CCPC (20/109, 18%). The CCPC showed a papillary or tubular/solid architecture, clear cytoplasm, low nuclear grade, and a distinct immunohistochemical profile (RCC−, vimentin+, CK7+, p504S−). ACDAC displayed a variety of architectural patterns, eosinophilic cytoplasm, high nuclear grade, intratumoral calcium oxalate deposits, and an immunohistochemical profile similar to type 2 papillary renal-cell carcinoma (RCC+, vimentin+, CK7−/+, p504S+). Less than 5% (3/69) of pathologically staged renal-cell carcinomas in end-stage kidneys presented with lymphogenous and/or hematogenous metastases.</p>
</abstract>
<kwd-group>
<kwd>end-stage kidney carcinomas</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The development of renal carcinoma is the most serious complication of acquired cystic kidney disease (ACD).<sup><xref ref-type="bibr" rid="bibr1-1066896911414273">1</xref><xref ref-type="bibr" rid="bibr2-1066896911414273"/><xref ref-type="bibr" rid="bibr3-1066896911414273"/><xref ref-type="bibr" rid="bibr4-1066896911414273"/><xref ref-type="bibr" rid="bibr5-1066896911414273"/><xref ref-type="bibr" rid="bibr6-1066896911414273"/><xref ref-type="bibr" rid="bibr7-1066896911414273"/><xref ref-type="bibr" rid="bibr8-1066896911414273"/><xref ref-type="bibr" rid="bibr9-1066896911414273"/><xref ref-type="bibr" rid="bibr10-1066896911414273"/>-<xref ref-type="bibr" rid="bibr11-1066896911414273">11</xref></sup> The risk is 100 times that of the normal population with an incidence ranging from 3% to 7%.<sup><xref ref-type="bibr" rid="bibr12-1066896911414273">12</xref></sup> Among these, recent studies have identified 2 distinct renal-cell neoplasms with unusual histological patterns that do not fit into the categories recognized in the current classification system.<sup><xref ref-type="bibr" rid="bibr13-1066896911414273">13</xref></sup> In this context, one group of renal-cell carcinomas shows predominant microcystic architecture, eosinophilic cytoplasm, high-grade nuclei, and intratumoral oxalate crystal deposits.<sup><xref ref-type="bibr" rid="bibr14-1066896911414273">14</xref>,<xref ref-type="bibr" rid="bibr15-1066896911414273">15</xref></sup> The neoplasm occurs only in kidneys with ACD—that is, acquired cystic kidney disease–associated carcinoma (ACDAC).<sup><xref ref-type="bibr" rid="bibr14-1066896911414273">14</xref>,<xref ref-type="bibr" rid="bibr16-1066896911414273">16</xref></sup> The other group of carcinomas shows papillary architecture, pure clear-cell cytology, and low-grade nuclei.<sup><xref ref-type="bibr" rid="bibr17-1066896911414273">17</xref>,<xref ref-type="bibr" rid="bibr18-1066896911414273">18</xref></sup> They occur in kidneys with both ACD and noncystic end-stage renal disease (ESRD)—that is, clear-cell papillary renal-cell carcinoma (CCPC).<sup><xref ref-type="bibr" rid="bibr13-1066896911414273">13</xref>,<xref ref-type="bibr" rid="bibr16-1066896911414273">16</xref><xref ref-type="bibr" rid="bibr17-1066896911414273"/>-<xref ref-type="bibr" rid="bibr18-1066896911414273">18</xref></sup> Only a few studies have addressed the immunohistochemical profiles and biological behavior of ACDAC and CCPC.<sup><xref ref-type="bibr" rid="bibr13-1066896911414273">13</xref>,<xref ref-type="bibr" rid="bibr17-1066896911414273">17</xref>,<xref ref-type="bibr" rid="bibr18-1066896911414273">18</xref></sup> The aim of this study is to investigate the morphological features, immunohistochemical profiles, and biological behavior of these unusual renal-cell neoplasms in comparison to conventional renal-cell carcinomas arising in kidneys with ESRD.</p>
<sec id="section1-1066896911414273" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>Primary tumor samples (n = 109) from patients with ESRD (n = 61) were retrieved from the files of the Pathology Department at University of Maryland Medical Center (<xref ref-type="table" rid="table1-1066896911414273">Table 1</xref>). In all, 53 patients had a unilateral nephrectomy, whereas both kidneys were removed in 8 cases. A definite positive history of hemodialysis was available in 53 cases with a duration ranging from 1 to 24 years. ACD was diagnosed according to previously published criteria: More than 3 cysts should be present, or more than 25% of the kidney should be involved with no history or evidence of polycystic kidney disease.<sup><xref ref-type="bibr" rid="bibr19-1066896911414273">19</xref></sup> Representative tissue sections from the surgical specimen were fixed in 10% buffered formalin and embedded in paraffin. For routine microscopy, 4-µm thick sections were stained with hematoxylin–eosin. All slides from the cases were reviewed, and the tumors resembling sporadic renal-cell carcinomas were classified according to the WHO (2004) classification system.<sup><xref ref-type="bibr" rid="bibr20-1066896911414273">20</xref></sup> Tumors that did not fulfill the morphological criteria of usual renal-cell neoplasms were designated as renal-cell carcinoma, unclassified. The unclassified carcinomas were later reevaluated for morphological features of the 2 subtypes of renal-cell carcinomas unique to ESRD, ACDAC, and CCPC.<sup><xref ref-type="bibr" rid="bibr13-1066896911414273">13</xref>,<xref ref-type="bibr" rid="bibr15-1066896911414273">15</xref><xref ref-type="bibr" rid="bibr16-1066896911414273"/><xref ref-type="bibr" rid="bibr17-1066896911414273"/>-<xref ref-type="bibr" rid="bibr18-1066896911414273">18</xref></sup> Fuhrman’s nuclear grading was applied to all carcinomas with the exception of the chromophobe renal-cell carcinoma.<sup><xref ref-type="bibr" rid="bibr21-1066896911414273">21</xref></sup> Cortical adenomas, oncocytomas, and urothelial carcinomas were excluded from the study. Immunohistochemical studies were performed on representative formalin-fixed paraffin-embedded tissue blocks from 64 tumors representing each tumor group: 16 type 1 papillary renal-cell carcinomas (PC1), 10 type 2 papillary renal-cell carcinomas (PC2), 2 solid type papillary renal-cell carcinomas (sPC), 10 clear-cell renal-cell carcinomas (CCRCCs), 3 chromophobe renal-cell carcinomas (CHRCs), 8 ACDACs, and 15 CCPCs. Immunohistochemical staining was performed using an automated immunostainer (BenchMark, Ventana, Tucson, AZ) and ultraview universal indirect biotin-free DAB detection kit. The following antibodies were used: RCC (prediluted, mouse monoclonal, Ventana), vimentin (prediluted, mouse monoclonal, Ventana), CK7 (prediluted, mouse monoclonal, Ventana), and p504S/AMACR (prediluted, mouse monoclonal, Cell Marque [Rocklin, CA]). Evaluation of the immunohistochemical staining was performed by light microscopy using a 10× objective lens with the selective use of a 20× to 40× objective lens for confirmation. A positive cytoplasmic and/or membranous expression in 10% or more of neoplastic cells qualified as “positive (+).” The renal-cell carcinomas were staged according to the 2010 UICC/AJCC consensus guidelines.<sup><xref ref-type="bibr" rid="bibr22-1066896911414273">22</xref></sup> The use of paraffin blocks for this study meets Institutional Review Board and Health Insurance Portability and Accountability Act requirements and has been approved by the institutional review board at the University of Maryland (HP-47559).</p>
<table-wrap id="table1-1066896911414273" position="float">
<label>Table 1.</label>
<caption>
<p>Renal-Cell Carcinomas in Kidneys With End-Stage Renal Disease<sup><xref ref-type="table-fn" rid="table-fn2-1066896911414273">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-1066896911414273" xlink:href="10.1177_1066896911414273-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Case</th>
<th align="center">Age/Sex</th>
<th align="center">Tumor/Kidney</th>
<th align="center">Diagnosis</th>
<th align="center">Grade</th>
<th align="center">Tumor Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>66/M</td>
<td>1/R</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>2</td>
<td>73/M</td>
<td>1/R</td>
<td><bold>sPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>3</td>
<td>59/M</td>
<td>1/L</td>
<td><bold>ACDAC</bold></td>
<td>3</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>4</td>
<td>90/M</td>
<td>1/L</td>
<td><bold>CCRCC</bold></td>
<td>1</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td/>
<td/>
<td>1/R</td>
<td><bold>CCRCC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>5</td>
<td>59/M</td>
<td>2/L</td>
<td><bold>ACDAC</bold>, CCRCC</td>
<td>3</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>6</td>
<td>71/M</td>
<td>1/L</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT2bNxMx</td>
</tr>
<tr>
<td>7</td>
<td>50/M</td>
<td>1/L</td>
<td><bold>PC2</bold> (sarc)</td>
<td>4</td>
<td>pT3aN1M1</td>
</tr>
<tr>
<td>8</td>
<td>58/F</td>
<td>1/R</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>9</td>
<td>83/M</td>
<td>2/R</td>
<td><bold>PC2</bold> (x2)</td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>10</td>
<td>59/M</td>
<td>1/R</td>
<td><bold>PC2</bold></td>
<td>3</td>
<td>pT1bN1Mx</td>
</tr>
<tr>
<td>11</td>
<td>60/M</td>
<td>2/R</td>
<td><bold>PC1</bold>, CCRCC</td>
<td>2</td>
<td>pT1bN0Mx</td>
</tr>
<tr>
<td>12</td>
<td>51/M</td>
<td>2/R</td>
<td>PC1, <bold>CCRCC</bold></td>
<td>2</td>
<td>pT1aN0Mx</td>
</tr>
<tr>
<td/>
<td/>
<td>1/L</td>
<td><bold>CCRCC</bold></td>
<td>2</td>
<td>pT1aN0Mx</td>
</tr>
<tr>
<td>13</td>
<td>61/M</td>
<td>2/R</td>
<td><bold>PC1</bold> (x2)</td>
<td>2</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>14</td>
<td>71/M</td>
<td>4/L</td>
<td><bold>PC1</bold> (x4)</td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>15</td>
<td>53/M</td>
<td>1/R</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>16</td>
<td>53/M</td>
<td>1/L</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>17</td>
<td>64/M</td>
<td>2/R</td>
<td>PC1, <bold>ACDAC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td/>
<td/>
<td>2/L</td>
<td><bold>PC1</bold> (x2)</td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>18</td>
<td>75/M</td>
<td>1/R</td>
<td><bold>CHRC</bold></td>
<td>n/a</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>19</td>
<td>73/M</td>
<td>1/R</td>
<td>PC1</td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>20</td>
<td>65/M</td>
<td>1/L</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>21</td>
<td>67/F</td>
<td>1/L</td>
<td><bold>ACDAC</bold></td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>22</td>
<td>60/F</td>
<td>1/R</td>
<td><bold>ACDAC</bold></td>
<td>3</td>
<td>pT1aN0Mx</td>
</tr>
<tr>
<td/>
<td/>
<td>1/L</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>23</td>
<td>59/M</td>
<td>3/R</td>
<td>CCPC(x2), <bold>PC2</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>24</td>
<td>54/F</td>
<td>1/R</td>
<td><bold>CCPC</bold></td>
<td>1</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>25</td>
<td>47/M</td>
<td>1/L</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>26</td>
<td>58/M</td>
<td>2/R</td>
<td><bold>PC1</bold>, ACDAC</td>
<td>3</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td/>
<td/>
<td>1/L</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>27</td>
<td>64/M</td>
<td>1/L</td>
<td><bold>PC2</bold></td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>28</td>
<td>58/M</td>
<td>1/R</td>
<td><bold>PC2</bold></td>
<td>3</td>
<td>pT2NxMx</td>
</tr>
<tr>
<td>29</td>
<td>44/M</td>
<td>1/L</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>30</td>
<td>64/M</td>
<td>2/L</td>
<td><bold>PC2</bold> (sarc), PC2</td>
<td>4</td>
<td>pT1aN1Mx</td>
</tr>
<tr>
<td>31</td>
<td>68/M</td>
<td>1/L</td>
<td><bold>CCRCC</bold></td>
<td>1</td>
<td>pT1aN0Mx</td>
</tr>
<tr>
<td>32</td>
<td>67/F</td>
<td>1/R</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>33</td>
<td>72/M</td>
<td>1/R</td>
<td><bold>CHRC</bold></td>
<td>n/a</td>
<td>pT1aN0Mx</td>
</tr>
<tr>
<td>34</td>
<td>60/M</td>
<td>1/R</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td/>
<td/>
<td>1/L</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>35</td>
<td>47/M</td>
<td>1/R</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT2aNxMx</td>
</tr>
<tr>
<td>36</td>
<td>66/M</td>
<td>1/L</td>
<td><bold>CCRCC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>37</td>
<td>51/F</td>
<td>1/L</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>38</td>
<td>56/M</td>
<td>1/L</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>39</td>
<td>69/M</td>
<td>4/L</td>
<td><bold>PC2</bold>(x2), PC1(x2)</td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>40</td>
<td>50/M</td>
<td>1/R</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>41</td>
<td>49/F</td>
<td>4/R</td>
<td><bold>ACDAC</bold>, PC1(x2), PC2</td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td/>
<td/>
<td>3/L</td>
<td>ACDAC, PC1, <bold>PC2</bold></td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>42</td>
<td>71/M</td>
<td>3/R</td>
<td><bold>PC2</bold>(x2), CHRC</td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td/>
<td/>
<td>1/L</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>43</td>
<td>57/M</td>
<td>3/L</td>
<td><bold>PC1</bold>(x2), PC2</td>
<td>3</td>
<td>pT2aNxMx</td>
</tr>
<tr>
<td>44</td>
<td>40/F</td>
<td>1/L</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>45</td>
<td>46/M</td>
<td>1/L</td>
<td><bold>ACDAC</bold></td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>46</td>
<td>61/M</td>
<td>1/L</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>47</td>
<td>87/M</td>
<td>3/L</td>
<td>PC1(x2), <bold>ACDAC</bold></td>
<td>3</td>
<td>pT2aN1Mx</td>
</tr>
<tr>
<td>48</td>
<td>65/M</td>
<td>2/R</td>
<td>ACDAC, <bold>CCRCC</bold></td>
<td>3</td>
<td>pT1aNoMx</td>
</tr>
<tr>
<td>49</td>
<td>49/M</td>
<td>1/R</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>50</td>
<td>59/F</td>
<td>1/L</td>
<td><bold>CHRC</bold></td>
<td>n/a</td>
<td>pT2aNxMx</td>
</tr>
<tr>
<td>51</td>
<td>49/M</td>
<td>2/L</td>
<td><bold>PC1</bold> (x2)</td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>52</td>
<td>53/F</td>
<td>1/R</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>53</td>
<td>50/M</td>
<td>1/L</td>
<td><bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>54</td>
<td>70/F</td>
<td>1/R</td>
<td><bold>CCPC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>55</td>
<td>56/M</td>
<td>4/R</td>
<td><bold>CCPC</bold> (x4)</td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>56</td>
<td>59/M</td>
<td>2/R</td>
<td>CCPC, <bold>PC1</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>57</td>
<td>64/F</td>
<td>3/R</td>
<td><bold>ACDAC</bold>, CCPC (x2)</td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>58</td>
<td>73/M</td>
<td>1/R</td>
<td><bold>CCRCC</bold></td>
<td>2</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>59</td>
<td>46/M</td>
<td>1/L</td>
<td><bold>ACDAC</bold></td>
<td>3</td>
<td>pT1aNxMx</td>
</tr>
<tr>
<td>60</td>
<td>63/F</td>
<td>1/L</td>
<td><bold>CCRCC</bold></td>
<td>2</td>
<td>pT1bNxMx</td>
</tr>
<tr>
<td>61</td>
<td>50/M</td>
<td>5/R</td>
<td>PC1 (x3), PC2, s<bold>PC</bold></td>
<td>3</td>
<td>pT1bNxMx</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896911414273">
<p>Abbreviations: R, right; L, left; PC1, type 1 papillary renal-cell carcinoma; PC2, type 2 papillary renal-cell carcinoma; sPC, solid papillary renal-cell carcinoma; CCRCC, clear-cell renal-cell carcinoma; CHRC, chromophobe renal-cell carcinoma; CCPC, clear-cell papillary renal-cell carcinoma; ACDAC, acquired cystic kidney disease–associated carcinoma; sarc, sarcomatoid component.</p>
</fn>
<fn id="table-fn2-1066896911414273">
<label>a</label>
<p>Tumor in bold: dominant tumor; grade: Fuhrman nuclear grade, dominant tumor; tumor stage: tumor stage, dominant tumor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section2-1066896911414273" sec-type="results">
<title>Results</title>
<p>The clinicopathological and immunohistochemical findings are listed in <xref ref-type="table" rid="table1-1066896911414273">Tables 1</xref> to <xref ref-type="table" rid="table3-1066896911414273">3</xref>. The study group comprised 47 men and 14 women (46 African American and 15 Caucasian) with a mean age of 61 years (range, 40-90 years; ratio of men to women, 3:1). Overall, of the 61 cases, 39 had ACD, whereas 22 showed kidneys with noncystic ESRD, and 22 of the 61 patients (36%) with ESRD presented with multifocal renal-cell carcinoma (<xref ref-type="fig" rid="fig1-1066896911414273">Figure 1</xref>). A total of 109 renal-cell carcinomas were identified (42 in kidneys with noncystic ESRD and 67 in kidneys with ACD (<xref ref-type="table" rid="table1-1066896911414273">Tables 1</xref> and <xref ref-type="table" rid="table2-1066896911414273">2</xref>). Three subtypes of renal-cell carcinoma morphologically similar to those found in sporadic settings were present, including papillary renal-cell carcinoma, CCRCC, and CHRC. In addition to the above-described neoplasms, 2 other distinctive renal-cell carcinoma types were present. The first subtype, CCPC, occurred in 20 out of the 109 cases (18.4%); 14 of the CCPCs occurred in the setting of ACD (70%) and 6 in noncystic ESRD (30%). The majority of CCPCs were well circumscribed, predominantly cystic (75%), and showed papillary architecture, clear cytoplasm, small- to intermediate-size round or irregular nuclei, and an inconspicuous nucleolus (<xref ref-type="fig" rid="fig2-1066896911414273">Figure 2</xref>). The nuclei were arranged toward the luminal surface. Stromal macrophages, necrosis, and calcifications were not observed. CCPCs showed a distinct immunoprofile, not seen in conventional renal-cell carcinomas (<xref ref-type="table" rid="table3-1066896911414273">Table 3</xref>). The neoplastic cells were positive for CK7 and vimentin and negative for RCC and p504S (<xref ref-type="fig" rid="fig3-1066896911414273">Figures 3</xref>-<xref ref-type="fig" rid="fig6-1066896911414273">6</xref>). Overall, 5 of the 20 (5/20, 25%) CCPCs had the distinct immunoprofile and showed predominant tubular/solid architecture, clear cytoplasm, and absence of true papillae (<xref ref-type="fig" rid="fig7-1066896911414273">Figures 7</xref>-<xref ref-type="fig" rid="fig11-1066896911414273">11</xref>). The other subtype, ACDAC (11.9%), occurred in kidneys all of which had ACD. The neoplasms were composed of a variable amount of microcysts, acini, papillae, and cribriform nests (<xref ref-type="fig" rid="fig12-1066896911414273">Figures 12</xref> and <xref ref-type="fig" rid="fig13-1066896911414273">13</xref>). The neoplastic cells contained abundant eosinophilic cytoplasm, large round nuclei with dispersed chromatin, and a prominent nucleolus. Focal prominent cytoplasmic vacuolation was also noted. Intratumoral oxalate crystals were present in the majority of the ACDAC (54%), but no oxalate crystals were observed in any of the other tumor types. Immunohistochemistry results were positive for RCC, vimentin, and p504S, and results were negative or focally positive for CK7 (<xref ref-type="fig" rid="fig14-1066896911414273">Figures 14</xref>-<xref ref-type="fig" rid="fig17-1066896911414273">17</xref>)—an immunoprofile similar to that observed in PC2 (<xref ref-type="table" rid="table3-1066896911414273">Table 3</xref>). Overall, 3 out of the 69 pathologically staged renal-cell carcinomas (&lt;5%) presented with lymphogeneous and/or hematogenous metastases (<xref ref-type="table" rid="table1-1066896911414273">Table 1</xref>). All metastatic neoplasms were PC2 (2/3 with sarcomatoid dedifferentiation).</p>
<table-wrap id="table2-1066896911414273" position="float">
<label>Table 2.</label>
<caption>
<p>Renal-Cell Carcinomas in Noncystic and Cystic End-Stage Renal Disease</p>
</caption>
<graphic alternate-form-of="table2-1066896911414273" xlink:href="10.1177_1066896911414273-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Diagnosis</th>
<th align="center">Noncystic (%)</th>
<th align="center">Cystic (%)</th>
<th align="center">Total (Noncystic and Cystic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCRCC</td>
<td>2/42 (4.8%)</td>
<td>9/67 (13.4%)</td>
<td>11/109 (10.1%)</td>
</tr>
<tr>
<td>PC1</td>
<td>19/42 (45.2%)</td>
<td>23/67 (34.4%)</td>
<td>42/109 (38.5%)</td>
</tr>
<tr>
<td>PC2</td>
<td>9/42 (21.4%)</td>
<td>8/67 (11.9%)</td>
<td>17/109 (15.6%)</td>
</tr>
<tr>
<td>sPC</td>
<td>2/42 (4.8%)</td>
<td>0/67 (0%)</td>
<td>2/109 (1.8%)</td>
</tr>
<tr>
<td>CHRC</td>
<td>4/42 (9.5%)</td>
<td>0/67 (0%)</td>
<td>4/109 (3.7%)</td>
</tr>
<tr>
<td>ACDAC</td>
<td>0/42 (0%)</td>
<td>13/67 (19.4%)</td>
<td>13/109 (11.9%)</td>
</tr>
<tr>
<td>CCPC</td>
<td>6/42 (14.3%)</td>
<td>14/67 (20.9%)</td>
<td>20/109 (18.4%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1066896911414273">
<p>Abbreviations: CCRCC, clear-cell renal-cell carcinoma; PC1, type 1 papillary renal-cell carcinoma; PC2, type 2 papillary renal-cell carcinoma; sPC, solid papillary renal-cell carcinoma; CHRC, chromophobe renal-cell carcinoma; ACDAC, acquired cystic kidney disease–associated carcinoma; CCPC, clear-cell papillary renal-cell carcinoma.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1066896911414273" position="float">
<label>Table 3.</label>
<caption>
<p>Immunoprofile of Renal-Cell Carcinomas in Kidneys With End-Stage Renal Disease</p>
</caption>
<graphic alternate-form-of="table3-1066896911414273" xlink:href="10.1177_1066896911414273-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Diagnosis</th>
<th align="center">RCC</th>
<th align="center">Vim</th>
<th align="center">CK7</th>
<th align="center">p504S</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCRCC</td>
<td>10/10 (100%)</td>
<td>10/10 (100%)</td>
<td>0/10 (0%)</td>
<td>0/10 (0%)</td>
</tr>
<tr>
<td>PC1</td>
<td>16/16 (100%)</td>
<td>16/16 (100%)</td>
<td>16/16 (100%)</td>
<td>16/16 (100%)</td>
</tr>
<tr>
<td>PC2</td>
<td>10/10 (100%)</td>
<td>10/10 (100%)</td>
<td>2/10 (20%)</td>
<td>10/10 (100%)</td>
</tr>
<tr>
<td>sPC</td>
<td>2/2 (100%)</td>
<td>2/2 (100%)</td>
<td>2/2 (100%)</td>
<td>2/2 (100%)</td>
</tr>
<tr>
<td>CHRC</td>
<td>0/3 (0%)</td>
<td>0/3 (0%)</td>
<td>3/3 (100%)</td>
<td>1/3 (33%)</td>
</tr>
<tr>
<td>ACDAC</td>
<td>8/8 (100%)</td>
<td>8/8 (100%)</td>
<td>1/8 (12.5%)</td>
<td>8/8 (100%)</td>
</tr>
<tr>
<td>CCPC</td>
<td>0/15 (0%)</td>
<td>15/15 (100%)</td>
<td>15/15 (100%)</td>
<td>0/15 (0%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1066896911414273">
<p>Abbreviations: CCRCC, clear-cell renal-cell carcinoma; PC1, type 1 papillary renal-cell carcinoma; PC2, type 2 papillary carcinoma; sPC, solid papillary renal-cell carcinoma; CHRC, chromophobe renal-cell carcinoma; ACDAC, acquired cystic kidney disease–associated carcinoma; CCPC, clear-cell papillary renal-cell carcinoma; Vim, vimentin.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1066896911414273" position="float">
<label>Figure 1.</label>
<caption>
<p>Multifocal renal-cell carcinoma in kidney with end-stage renal disease</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig1.tif"/></fig>
<fig id="fig2-1066896911414273" position="float">
<label>Figure 2.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma: note papillary architecture and clear cytoplasm (hematoxylin and eosin, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig2.tif"/></fig>
<fig id="fig3-1066896911414273" position="float">
<label>Figure 3.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma: RCC is negative in neoplastic cells (RCC, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig3.tif"/>
</fig>
<fig id="fig4-1066896911414273" position="float">
<label>Figure 4.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma: vimentin is positive in neoplastic cells (vimentin, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig4.tif"/>
</fig>
<fig id="fig5-1066896911414273" position="float">
<label>Figure 5.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma: CK7 is positive in neoplastic cells (CK7, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig5.tif"/>
</fig>
<fig id="fig6-1066896911414273" position="float">
<label>Figure 6.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma: P504S is negative in neoplastic cells (p504S, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig6.tif"/>
</fig>
<fig id="fig7-1066896911414273" position="float">
<label>Figure 7.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma with tubular/solid architecture (hematoxylin and eosin, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig7.tif"/>
</fig>
<fig id="fig8-1066896911414273" position="float">
<label>Figure 8.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma with tubular/solid architecture: RCC is negative in neoplastic cells (RCC, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig8.tif"/>
</fig>
<fig id="fig9-1066896911414273" position="float">
<label>Figure 9.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma with tubular/solid architecture: vimentin is positive in neoplastic cells (vimentin, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig9.tif"/>
</fig>
<fig id="fig10-1066896911414273" position="float">
<label>Figure 10.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma with tubular/solid architecture: CK7 is positive in neoplastic cells (CK7, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig10.tif"/>
</fig>
<fig id="fig11-1066896911414273" position="float">
<label>Figure 11.</label>
<caption>
<p>Clear-cell papillary renal-cell carcinoma with tubular/solid architecture: P504S is negative in neoplastic cells (p504S, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig11.tif"/>
</fig>
<fig id="fig12-1066896911414273" position="float">
<label>Figure 12.</label>
<caption>
<p>Acquired cystic kidney disease–associated carcinoma. Note acinar architecture, eosinophilic cytoplasm, high-grade nuclei, and calcium oxalate deposits (hematoxylin and eosin, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig12.tif"/>
</fig>
<fig id="fig13-1066896911414273" position="float">
<label>Figure 13.</label>
<caption>
<p>Acquired cystic kidney disease–associated carcinoma: note papillary architecture, eosinophilic cytoplasm, high-grade nuclei, and calcium oxalate deposits (hematoxylin and eosin, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig13.tif"/>
</fig>
<fig id="fig14-1066896911414273" position="float">
<label>Figure 14.</label>
<caption>
<p>Acquired cystic kidney disease–associated carcinoma: RCC is positive in neoplastic cells (RCC, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig14.tif"/>
</fig>
<fig id="fig15-1066896911414273" position="float">
<label>Figure 15.</label>
<caption>
<p>Acquired cystic kidney disease–associated carcinoma: vimentin is positive in neoplastic cells (vimentin, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig15.tif"/>
</fig>
<fig id="fig16-1066896911414273" position="float">
<label>Figure 16.</label>
<caption>
<p>Acquired cystic kidney disease–associated carcinoma: note focal CK7 positivity (CK7, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig16.tif"/>
</fig>
<fig id="fig17-1066896911414273" position="float">
<label>Figure 17.</label>
<caption>
<p>Acquired cystic kidney disease–associated carcinoma: P504S is positive in neoplastic cells (p504S, 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896911414273-fig17.tif"/>
</fig>
</sec>
<sec id="section3-1066896911414273" sec-type="discussion">
<title>Discussion</title>
<p>The present clinicopathological and immunohistochemical study of renal-cell carcinomas in ESRD is one of the largest published in the literature. The data show that the histological spectrum of renal-cell carcinomas in kidneys with ESRD differs from those arising in the setting of non-ESRD: conventional papillary renal-cell carcinoma (all subtypes combined, 56%) and CCPC (18%) were the predominant subtypes in patients with ESRD, whereas CCRCC (70%-80%) and papillary renal-cell carcinoma (10%-15%) comprised the major histological subtypes of sporadic renal-cell neoplasms within the general population.<sup><xref ref-type="bibr" rid="bibr20-1066896911414273">20</xref>,<xref ref-type="bibr" rid="bibr23-1066896911414273">23</xref></sup> Among the papillary renal-cell carcinomas, PC1 was by far the most common malignant neoplasm in both noncystic (19/42, 45.2%) and acquired cystic (23/67, 34.4%) ESRD. When applying the previously published diagnostic criteria,<sup><xref ref-type="bibr" rid="bibr16-1066896911414273">16</xref>,<xref ref-type="bibr" rid="bibr20-1066896911414273">20</xref></sup> the morphological diagnosis of PC1 was straightforward in the vast majority of cases. In addition, the neoplasm displayed a distinct immunohistochemical profile (coexpression of RCC, vimentin, CK7, and p504S) not seen in the majority of PC2 or in other renal-cell carcinomas (<xref ref-type="table" rid="table3-1066896911414273">Table 3</xref>). CCPC was more common than any other subtype of renal-cell carcinoma (20/109, 18.4%), with the exception of PC1. The study demonstrated a distinct immunohistochemical profile: coexpression of CK7 and vimentin and negative RCC and p504S. The cytogenetic findings in CCPC were also different from those usually seen in papillary renal-cell carcinoma or CCRCC.<sup><xref ref-type="bibr" rid="bibr17-1066896911414273">17</xref>,<xref ref-type="bibr" rid="bibr18-1066896911414273">18</xref></sup> Recent studies demonstrated that CCPC lacked the gains of chromosome 7 and losses of chromosome Y that are typical of papillary renal-cell carcinoma.<sup><xref ref-type="bibr" rid="bibr17-1066896911414273">17</xref>,<xref ref-type="bibr" rid="bibr18-1066896911414273">18</xref></sup> Deletion of 3p, usually seen in CCRCC, was not detected.<sup><xref ref-type="bibr" rid="bibr18-1066896911414273">18</xref></sup> Distinguishing CCPC from papillary renal-cell carcinoma is not particularly difficult, although an accurate classification of some histological variants, such as papillary renal-cell carcinoma with extensive clear-cell change and renal-cell carcinoma with mixed features of papillary and clear-cell cytomorphology can be challenging.<sup><xref ref-type="bibr" rid="bibr24-1066896911414273">24</xref>,<xref ref-type="bibr" rid="bibr25-1066896911414273">25</xref></sup> In this context, papillary renal-cell carcinoma with clear cells is a novel entity with a unique immunohistochemical and cytogenetic phenotype and poorer prognosis.<sup><xref ref-type="bibr" rid="bibr24-1066896911414273">24</xref></sup> Unlike CCPC, papillary carcinoma with clear cells expressed p504S (100%) and demonstrated loss of chromosome 3p material in the majority (75%) of cases.<sup><xref ref-type="bibr" rid="bibr24-1066896911414273">24</xref></sup> According to recent publications, ACDAC occurred only in the setting of ACD and is the most common subtype in ESRD.<sup><xref ref-type="bibr" rid="bibr15-1066896911414273">15</xref>,<xref ref-type="bibr" rid="bibr16-1066896911414273">16</xref></sup> However, ACDAC was the third most common renal-cell carcinoma subtype in kidneys with ACD in this study (13/109, 11.9%). The morphological features of ACDAC have a significant overlap with the features of PC2: (1) papillary architecture almost invariably present, at least focally; (2) eosinophilic tumor cells with large nuclei and prominent nucleoli; and (3) an immunoprofile identical to that of PC2 (RCC+, vimentin+, CK7−/+, and p504S+). In agreement with our observations, previous studies demonstrated CK7 negativity in 24/30 (80%) PC2.<sup><xref ref-type="bibr" rid="bibr26-1066896911414273">26</xref></sup> On the other hand, ACDAC displays some morphological features different from papillary renal-cell carcinoma: variable composition of different architectural patterns and intratumoral calcium oxalate crystals. Extensive calcium oxalate crystal deposits appear to be a distinct morphological feature of ACDAC. No oxalate crystals were observed in any of the other tumor types. However, previous case report studies demonstrated calcium oxalate crystals in papillary renal-cell carcinomas and CCRCCs arising in the setting of ACD.<sup><xref ref-type="bibr" rid="bibr19-1066896911414273">19</xref>,<xref ref-type="bibr" rid="bibr27-1066896911414273">27</xref>,<xref ref-type="bibr" rid="bibr28-1066896911414273">28</xref></sup> The possibility of these tumors representing ACDAC with a predominant papillary or clear-cell phenotype cannot be completely excluded based on the illustrations provided. The pathogenesis of oxalate crystal deposition in this tumor type is not clear. Physiologically, oxalate is eliminated by renal proximal tubular cells, and the formation of oxalate crystals is inhibited by nephrocalcin, an acidic glycoprotein.<sup><xref ref-type="bibr" rid="bibr28-1066896911414273">28</xref></sup> Nephrocalcin is produced by proximal renal tubule cells but has also been localized to cells of primary renal carcinomas.<sup><xref ref-type="bibr" rid="bibr19-1066896911414273">19</xref></sup> Patients undergoing long-term hemodialysis often have decreased levels of nephrocalcin.<sup><xref ref-type="bibr" rid="bibr19-1066896911414273">19</xref></sup> Whether calcium oxalate plays any role in tumor development is not clear.<sup><xref ref-type="bibr" rid="bibr28-1066896911414273">28</xref></sup></p>
<p>The nature of renal-cell neoplasms in end-stage kidneys remains unknown.<sup><xref ref-type="bibr" rid="bibr29-1066896911414273">29</xref></sup> Moreover, limited information about the genetic makeup of these neoplasms is available. Previous studies have provided conflicting data regarding the significance of the number of frequently recurring abnormalities. For example, Hes et al<sup><xref ref-type="bibr" rid="bibr30-1066896911414273">30</xref></sup> reported that gains of chromosomes 7 and 17 are very frequent in nonneoplastic parenchyma of ESRD, papillary adenomas, and papillary renal-cell carcinomas. The data suggest that these chromosomal abnormalities may predispose individuals to multifocal papillary lesions.<sup><xref ref-type="bibr" rid="bibr30-1066896911414273">30</xref></sup> Other studies showed that a combined trisomy of chromosomes 7 and 17, which is highly characteristic of papillary renal-cell tumors in the general population, is rarely found in papillary renal-cell tumors of end-stage kidneys.<sup><xref ref-type="bibr" rid="bibr29-1066896911414273">29</xref>,<xref ref-type="bibr" rid="bibr31-1066896911414273">31</xref></sup> According to Kovacs,<sup><xref ref-type="bibr" rid="bibr29-1066896911414273">29</xref></sup> the diffuse expression of growth factors at a high level in ACD may replace the dosage effect of trisomy 7 and 17 and result in the activation of dormant embryonic nephrogenic cells. Thus, the initial step might account for differences in the genetic changes of papillary renal-cell tumor development that are seen in the general population and in patients with end-stage renal failure. The additional chromosomal changes (loss of chromosome Y and trisomy of chromosome 16) leading to malignant growth seem to be similar in both cases.<sup><xref ref-type="bibr" rid="bibr29-1066896911414273">29</xref></sup> Also, there is little consensus concerning the diagnostic significance of a number of frequently recurring abnormalities in ACDAC. In a recent study, the G-band karyotype of ACDAC showed 49, X, +X, −Y, +3, +7, +16 resembling those of previously reported sporadic papillary renal-cell carcinomas.<sup><xref ref-type="bibr" rid="bibr32-1066896911414273">32</xref></sup> On the other hand, fluorescence in situ hybridization analysis showed gains of chromosomes 1, 2, 6, and 10 and no losses or gains of chromosome17 in ACDAC, a genetic profile distinct from the renal-cell neoplasms recognized in the current classification of renal-cell neoplasia.<sup><xref ref-type="bibr" rid="bibr15-1066896911414273">15</xref></sup> The discrepancy in the reported frequency and immunohistochemical and cytogenetic profiles of renal-cell carcinoma subtypes in ESRD is explained most likely by the relatively small sample sizes; other possibilities include different methodologies and antibody types used in the previous studies.</p>
<p>Approximately 25% to 30% of patients with sporadic renal-cell carcinomas have metastatic disease at diagnosis.<sup><xref ref-type="bibr" rid="bibr33-1066896911414273">33</xref></sup> Our study demonstrated metastases in less than 5% (3/69) of the pathologically staged renal-cell carcinomas. In contrast to what was reported by Tickoo et al,<sup><xref ref-type="bibr" rid="bibr13-1066896911414273">13</xref></sup> none of the ACDACs was associated with metastatic disease. All metastatic renal-cell neoplasms in the setting of ESRD were PC2 (2/3 with sarcomatoid dedifferentiation). The data suggest that the biological behavior of renal-cell carcinomas in ESRD is more indolent in comparison to renal-cell neoplasms in the general population.</p>
<p>Finally, our observations as well as previously published data in the literature suggest that CCPC and ACDAC have morphological features distinct from the renal-cell neoplasms recognized in the current WHO classification of renal-cell neoplasia and should be considered as a separate clinicopathological entity in the spectrum of renal-cell carcinomas. We suggest that a large-scale study will be needed to clarify the relationship between ACDAC and PC2. In cases where the distinction between CCPC and other renal-cell neoplasms is problematic, a limited immunohistochemical panel (RCC, vimentin, p504S, and CK7) can be a useful diagnostic tool in conjunction with the hematoxylin and eosin–stained tissue sections.</p>
</sec>
</body>
<back>
<ack><p>We gratefully acknowledge Dr Max Fischer and Dr Fabio Tavora for providing the macroscopic photograph and technical assistance.</p></ack>
<fn-group>
<fn fn-type="conflict">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896911414273">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Truong</surname><given-names>LD</given-names></name>
<name><surname>Krishnan</surname><given-names>B</given-names></name>
<name><surname>Cao</surname><given-names>JT</given-names></name>
<name><surname>Barrios</surname><given-names>R</given-names></name>
<name><surname>Suki</surname><given-names>WN</given-names></name>
</person-group>. <article-title>Renal neoplasm in acquired cystic kidney disease</article-title>. <source>Am J Kidney Dis</source>. <year>1995</year>;<volume>26</volume>:<fpage>1</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr2-1066896911414273">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonsib</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Renal cystic disease and renal neoplasms: a mini review</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2009</year>;<volume>4</volume>:<fpage>1998</fpage>-<lpage>2007</lpage>.</citation>
</ref>
<ref id="bibr3-1066896911414273">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughson</surname><given-names>MD</given-names></name>
<name><surname>Meloni</surname><given-names>AM</given-names></name>
<name><surname>Silva</surname><given-names>FG</given-names></name>
<name><surname>Sandberg</surname><given-names>AA</given-names></name>
</person-group>. <article-title>Renal cell carcinoma in an end-stage kidney of a patient with a functional transplant: cytogenetic and molecular genetic findings</article-title>. <source>Cancer Genet Cytogenet</source>. <year>1996</year>;<volume>89</volume>:<fpage>65</fpage>-<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr4-1066896911414273">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoshida</surname><given-names>Y</given-names></name>
<name><surname>Nakanishi</surname><given-names>H</given-names></name>
<name><surname>Shin</surname><given-names>M</given-names></name>
<name><surname>Satoh</surname><given-names>T</given-names></name>
<name><surname>Hanai</surname><given-names>J</given-names></name>
<name><surname>Aozasa</surname><given-names>K</given-names></name>
</person-group>. <article-title>Renal neoplasias in patients receiving dialysis and renal transplantation: clinico-pathological features and p53 gene mutations</article-title>. <source>Transplantation</source>. <year>1999</year>;<volume>68</volume>:<fpage>385</fpage>-<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr5-1066896911414273">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savaj</surname><given-names>S</given-names></name>
<name><surname>Liakopoulos</surname><given-names>V</given-names></name>
<name><surname>Ghareeb</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Renal cell carcinoma in peritoneal dialysis patients</article-title>. <source>Int Urol Nephrol</source>. <year>2003</year>;<volume>35</volume>:<fpage>263</fpage>-<lpage>265</lpage>.</citation>
</ref>
<ref id="bibr6-1066896911414273">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Denton</surname><given-names>MD</given-names></name>
<name><surname>Magee</surname><given-names>CC</given-names></name>
<name><surname>Ovuworie</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis</article-title>. <source>Kidney Int</source>. <year>2002</year>;<volume>61</volume>:<fpage>2201</fpage>-<lpage>2209</lpage>.</citation>
</ref>
<ref id="bibr7-1066896911414273">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughson</surname><given-names>MD</given-names></name>
<name><surname>Buchwald</surname><given-names>D</given-names></name>
<name><surname>Fox</surname><given-names>M</given-names></name>
</person-group>. <article-title>Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis</article-title>. <source>Arch Pathol Lab Med</source>. <year>1986</year>;<volume>110</volume>:<fpage>592</fpage>-<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr8-1066896911414273">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dunnill</surname><given-names>MS</given-names></name>
<name><surname>Millard</surname><given-names>PR</given-names></name>
<name><surname>Oliver</surname><given-names>D</given-names></name>
</person-group>. <article-title>Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis</article-title>. <source>J Clin Pathol</source>. <year>1977</year>;<volume>30</volume>:<fpage>868</fpage>-<lpage>877</lpage>.</citation>
</ref>
<ref id="bibr9-1066896911414273">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matson</surname><given-names>MA</given-names></name>
<name><surname>Cohen</surname><given-names>EP</given-names></name>
</person-group>. <article-title>Acquired cystic kidney disease: occurrence, prevalence, and renal cancers</article-title>. <source>Medicine (Baltimore)</source>. <year>1990</year>;<volume>69</volume>:<fpage>217</fpage>-<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr10-1066896911414273">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farivar-Mohseni</surname><given-names>H</given-names></name>
<name><surname>Perlmutter</surname><given-names>AE</given-names></name>
<name><surname>Wilson</surname><given-names>S</given-names></name>
<name><surname>Shingleton</surname><given-names>WB</given-names></name>
<name><surname>Bigler</surname><given-names>SA</given-names></name>
<name><surname>Fowler</surname><given-names>JE</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Renal cell carcinoma and end stage renal disease</article-title>. <source>J Urol</source>. <year>2006</year>;<volume>175</volume>:<fpage>2018</fpage>-<lpage>2020</lpage>.</citation>
</ref>
<ref id="bibr11-1066896911414273">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Satoh</surname><given-names>S</given-names></name>
<name><surname>Tsuchiya</surname><given-names>N</given-names></name>
<name><surname>Habuchi</surname><given-names>T</given-names></name>
<name><surname>Ishiyama</surname><given-names>T</given-names></name>
<name><surname>Seimo</surname><given-names>K</given-names></name>
<name><surname>Kato</surname><given-names>T</given-names></name>
</person-group>. <article-title>Renal cell and transitional cell carcinoma in a Japanese population undergoing maintenance dialysis</article-title>. <source>J Urol</source>. <year>2005</year>;<volume>174</volume>:<fpage>1749</fpage>-<lpage>1753</lpage>.</citation>
</ref>
<ref id="bibr12-1066896911414273">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rivera</surname><given-names>M</given-names></name>
<name><surname>Tickoo</surname><given-names>SK</given-names></name>
<name><surname>Saqi</surname><given-names>A</given-names></name>
<name><surname>Lin</surname><given-names>O</given-names></name>
</person-group>. <article-title>Cytologic findings of acquired cystic disease-associated renal cell carcinoma: a report of two cases</article-title>. <source>Diagn Cytopathol</source>. <year>2008</year>;<volume>36</volume>:<fpage>344</fpage>-<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr13-1066896911414273">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tickoo</surname><given-names>SK</given-names></name>
<name><surname>dePeralta-Venturina</surname><given-names>MN</given-names></name>
<name><surname>Harik</surname><given-names>LR</given-names></name>
<etal/>
</person-group>. <article-title>Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia</article-title>. <source>Am J Surg Pathol</source>. <year>2006</year>;<volume>30</volume>:<fpage>141</fpage>-<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr14-1066896911414273">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sule</surname><given-names>N</given-names></name>
<name><surname>Yakupoglu</surname><given-names>U</given-names></name>
<name><surname>Shen</surname><given-names>SS</given-names></name>
<etal/>
</person-group>. <article-title>Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study</article-title>. <source>Am J Surg Pathol</source>. <year>2005</year>;<volume>29</volume>:<fpage>443</fpage>-<lpage>451</lpage>.</citation>
</ref>
<ref id="bibr15-1066896911414273">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cossu-Rocca</surname><given-names>P</given-names></name>
<name><surname>Eble</surname><given-names>JN</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Martignoni</surname><given-names>G</given-names></name>
<name><surname>Brunelli</surname><given-names>M</given-names></name>
<name><surname>Cheng</surname><given-names>L</given-names></name>
</person-group>. <article-title>Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study</article-title>. <source>Mod Pathol</source>. <year>2006</year>;<volume>19</volume>:<fpage>780</fpage>-<lpage>787</lpage>.</citation>
</ref>
<ref id="bibr16-1066896911414273">
<label>16.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Bostwick</surname><given-names>DG</given-names></name>
<name><surname>Cheng</surname><given-names>L</given-names></name>
</person-group>, eds. <source>Urologic Surgical Pathology</source>. <edition>2nd ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Mosby Elsevier</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr17-1066896911414273">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gobbo</surname><given-names>S</given-names></name>
<name><surname>Eble</surname><given-names>JN</given-names></name>
<name><surname>Grignon</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. <article-title>Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity</article-title>. <source>Am J Surg Pathol</source>. <year>2008</year>;<volume>32</volume>:<fpage>1239</fpage>-<lpage>1245</lpage>.</citation>
</ref>
<ref id="bibr18-1066896911414273">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gobbo</surname><given-names>S</given-names></name>
<name><surname>Eble</surname><given-names>JN</given-names></name>
<name><surname>Maclennan</surname><given-names>GT</given-names></name>
<etal/>
</person-group>. <article-title>Renal cell carcinoma with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis</article-title>. <source>Am J Surg Pathol</source>. <year>2008</year>;<volume>32</volume>:<fpage>1780</fpage>-<lpage>1786</lpage>.</citation>
</ref>
<ref id="bibr19-1066896911414273">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rioux-Leclercq</surname><given-names>NC</given-names></name>
<name><surname>Epstein</surname><given-names>JI</given-names></name>
</person-group>. <article-title>Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney</article-title>. <source>Arch Pathol Lab Med</source>. <year>2003</year>;<volume>127</volume>:<fpage>E89</fpage>-<lpage>E92</lpage>.</citation>
</ref>
<ref id="bibr20-1066896911414273">
<label>20.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Eble</surname><given-names>JN</given-names></name>
<name><surname>Sauter</surname><given-names>G</given-names></name>
<name><surname>Epstein</surname><given-names>JI</given-names></name>
<name><surname>Sesterhenn</surname><given-names>IA</given-names></name>
</person-group>, eds. <source>World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs</source>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <year>2004</year>.</citation>
</ref>
<ref id="bibr21-1066896911414273">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delahunt</surname><given-names>B</given-names></name>
<name><surname>Sika-Paotonu</surname><given-names>D</given-names></name>
<name><surname>Bethwaite</surname><given-names>PB</given-names></name>
<etal/>
</person-group>. <article-title>Fuhrman grading is not appropriate for chromophobe renal cell carcinoma</article-title>. <source>Am J Surg Pathol</source>. <year>2007</year>;<volume>31</volume>:<fpage>957</fpage>-<lpage>960</lpage>.</citation>
</ref>
<ref id="bibr22-1066896911414273">
<label>22.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Edge</surname><given-names>SB</given-names></name>
<name><surname>Byrd</surname><given-names>DR</given-names></name>
<name><surname>Compton</surname><given-names>CC</given-names></name>
<name><surname>Fritz</surname><given-names>AG</given-names></name>
<name><surname>Greene</surname><given-names>FL</given-names></name>
<name><surname>Trotti</surname><given-names>A</given-names><suffix>III</suffix></name>
</person-group>, eds. <source>AJCC Cancer Staging Manual</source>. <edition>7th ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr23-1066896911414273">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughson</surname><given-names>MD</given-names></name>
<name><surname>Schmidt</surname><given-names>L</given-names></name>
<name><surname>Zbar</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study</article-title>. <source>J Am Soc Nephrol</source>. <year>1996</year>;<volume>7</volume>:<fpage>2461</fpage>-<lpage>2468</lpage>.</citation>
</ref>
<ref id="bibr24-1066896911414273">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klatte</surname><given-names>T</given-names></name>
<name><surname>Said</surname><given-names>JW</given-names></name>
<name><surname>Seligson</surname><given-names>DB</given-names></name>
<etal/>
</person-group>. <article-title>Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features</article-title> <source>J Urol</source>. <year>2011</year>;<volume>185</volume>:<fpage>30</fpage>-<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr25-1066896911414273">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mai</surname><given-names>KT</given-names></name>
<name><surname>Faraji</surname><given-names>H</given-names></name>
<name><surname>Desantis</surname><given-names>D</given-names></name>
<name><surname>Robertson</surname><given-names>SJ</given-names></name>
<name><surname>Belanger</surname><given-names>EC</given-names></name>
<name><surname>Levac</surname><given-names>J</given-names></name>
</person-group>. <article-title>Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study</article-title>. <source>Virchows Arch</source>. <year>2010</year>;<volume>456</volume>:<fpage>77</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr26-1066896911414273">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delahunt</surname><given-names>B</given-names></name>
<name><surname>Eble</surname><given-names>JN</given-names></name>
</person-group>. <article-title>Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors</article-title>. <source>Mod Pathol</source>. <year>1997</year>;<volume>10</volume>:<fpage>537</fpage>-<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr27-1066896911414273">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dry</surname><given-names>SM</given-names></name>
<name><surname>Renshaw</surname><given-names>AA</given-names></name>
</person-group>. <article-title>Extensive calcium oxalate crystal deposition in papillary renal cell carcinoma: report of two cases</article-title>. <source>Arch Pathol Lab Med</source>. <year>1998</year>;<volume>122</volume>:<fpage>260</fpage>-<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr28-1066896911414273">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zamin-Khameh</surname><given-names>N</given-names></name>
<name><surname>Zhai</surname><given-names>Q</given-names></name>
<name><surname>Truong</surname><given-names>LD</given-names></name>
</person-group>. <article-title>Renal cell carcinoma with calcium oxalate deposition: a distinct type of renal cell carcinoma within the spectrum of renal neoplasms associated with acquired cystic kidney disease</article-title>. <source>Pathol Case Rev</source>. <year>2010</year>;<volume>15</volume>:<fpage>14</fpage>-<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr29-1066896911414273">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kovacs</surname><given-names>G</given-names></name>
</person-group>. <article-title>High frequency of papillary renal-cell tumours in end-stage kidneys: is there a molecular genetic explanation?</article-title> <source>Nephrol Dial Transplant</source>. <year>1995</year>;<volume>10</volume>:<fpage>593</fpage>-<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr30-1066896911414273">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hes</surname><given-names>O</given-names></name>
<name><surname>Sima</surname><given-names>R</given-names></name>
<name><surname>Nemcova</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>End-stage kidney disease: gains of chromosome 7 and 17 and loss of Y chromosome in non-neoplastic tissue</article-title>. <source>Virchows Arch</source>. <year>2008</year>;<volume>453</volume>:<fpage>313</fpage>-<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr31-1066896911414273">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughson</surname><given-names>MD</given-names></name>
<name><surname>Bigler</surname><given-names>S</given-names></name>
<name><surname>Dickman</surname><given-names>K</given-names></name>
<name><surname>Kovacs</surname><given-names>G</given-names></name>
</person-group>. <article-title>Renal cell carcinoma of end-stage renal disease: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification</article-title>. <source>Mod Pathol</source>. <year>1999</year>;<volume>12</volume>:<fpage>301</fpage>-<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr32-1066896911414273">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuroda</surname><given-names>N</given-names></name>
<name><surname>Shiotsu</surname><given-names>T</given-names></name>
<name><surname>Hes</surname><given-names>O</given-names></name>
<name><surname>Michal</surname><given-names>M</given-names></name>
<name><surname>Shuin</surname><given-names>T</given-names></name>
<name><surname>Lee</surname><given-names>GH</given-names></name>
</person-group>. <article-title>Acquired cystic disease-associated renal cell carcinoma with gain of chromosomes 3, 7, and 16, gain of chromosome X, and loss of chromosome Y</article-title>. <source>Med Mol Morphol</source>. <year>2010</year>;<volume>43</volume>:<fpage>231</fpage>-<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr33-1066896911414273">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curti</surname><given-names>BD</given-names></name>
</person-group>. <article-title>Renal cell carcinoma</article-title>. <source>JAMA</source>. <year>2004</year>;<volume>292</volume>:<fpage>97</fpage>-<lpage>100</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>